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Abstract20
A series of 5-fluorouracil (5-FU) loaded core/shell electrospun fibers is reported. The fibers21
have shells made of Eudragit S100 (ES-100), and drug-loaded cores comprising22
poly(vinylpyrrolidone), ethyl cellulose, ES-100, or drug alone. Monolithic 5-FU loaded ES-10023
fibers were also prepared for comparison. Electron microscopy showed all the fibers to have24
smooth cylindrical shapes, and clear core-shell structures were visible for all samples except25
the monolithic fibers. 5-FU was present in the amorphous physical form in all the materials26
prepared. Dissolution studies showed that the ES-100 shell was not able to prevent drug27
release at pH 1.0, even though the polymer is completely insoluble at this pH: around 30 to28
80 % of the maximum drug release was reached after 2h immersion at pH 1.0. These29
observations are ascribed to the low molecular weight of 5-FU permitting it to diffuse30
through pores in the ES-100 coating, and the high acid solubility of the drug providing a31
thermodynamic impetus for this to happen. In addition, the fibers were observed to be32
broken or merged following 2h at pH 1.0, providing additional escape routes for the 5-FU.33
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1. Introduction42
Electrospinning is a facile technique which has been widely explored in pharmaceutics43
(Chakraborty et al., 2009; Williams et al., 2012). In its simplest embodiment, a polymer is44
dissolved in a volatile solvent and ejected from a syringe fitted with a metal needle45
(spinneret) towards a metal collector at a controlled rate. The application of a high (kV)46
voltage between the spinneret and the collector causes the rapid evaporation of solvent,47
and results in the formation of nanoscale one-dimensional polymer fibers on the collector. If48
an active pharmaceutical ingredient (API) is co-dissolved with the polymer then drug-loaded49
fibers can be prepared, and these have been investigated for use as a broad range of drug50
delivery systems including fast-dissolving (Balogh et al., 2015; Li et al., 2013a; Li et al.,51
2013b; Nagy et al., 2010; Samprasit et al., 2015), sustained release (Chen et al., 2010b;52
Okuda et al., 2010; Xie and Wang, 2006; Xu et al., 2011), pulsatile release (Kaassis et al.,53
2014), and targeted release formulations (Abdullah et al., 2011; Shen et al., 2011; Yu et al.,54
2014). In recent years, researchers have developed increasing complex electrospinning55
experiments, and the use of coaxial electrospinning (which uses a concentric spinneret, with56
one needle nested inside another) to prepare core/shell structures has been very widely57
reported (Chakraborty et al., 2009; Chen et al., 2010a; Llorens et al., 2015).58
59
A common way to achieve targeted drug release is to use a pH-sensitive polymer to ensure60
that the API is freed only in a certain part of the gastro-intestinal tract. An enteric coating to61
a tablet or capsule to preclude drug release in the stomach is perhaps the simplest and most62
commonly employed embodiment of this. A range of pH-sensitive polymers exists, such as63
alginates, chitosan, poly(methacrylic acid-grafted-poly(ethylene glycol)) (Lowman et al.,64
1999), or poly(methacrylic acid-co-N-vinylpyrrolidone) (Carr and Peppas, 2010). One such65
family of materials, the Eudragit methacrylate polymers, has been widely used in the66
formulation of oral dosage forms including as tablet coatings or tablet matrices, and to67
prepare microspheres and nanoparticles for controlled drug delivery in the gastro-intestinal68
(GI) tract (Krishnaiah et al., 2002; Momoh et al., 2014; Varshosaz et al., 2015). Eudragit L100,69
L100-55 and S100 are specifically designed for targeting the lower parts of the GI tract;70
these fibers are insoluble at low pH, dissolving only at pH 6.0, 5.5, or 7.0 respectively.71
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72
Shen et al (Shen et al., 2011) were the first to fabricate electrospun Eudragit fibers, making73
materials of the Eudragit L100-55 (EL-100-55) polymer and diclofenac sodium. In74
vitro dissolution tests revealed that the fibers had pH-dependent release profiles, with very75
limited (less than 3%) diclofenac release at pH 1.0, but sustained and complete drug release76
over 6 hours at pH 6.8. A second study prepared analogous fibers using coaxial spinning with77
a mixture of ethanol and dimethylacetamide as the sheath fluid, which was reported to yield78
better quality fibers (Yu et al., 2014); again, very little drug was released in the acidic79
medium (< 5 %). Similar results have been seen for systems comprising EL-100-55 and80
ketoprofen (Yu et al., 2013b), helicid (Yu et al., 2013a), and mebeverine hydrochloride81
(Illangakoon et al., 2014). In other work, Aguilar et al. made blend fibers of EL-100-55 and82
poly(urethane) with paclitaxel, and saw very little release at pH 4 but much greater release83
at pH 6 (Aguilar et al., 2015). Eudragit S100 (ES-100) fibers containing uranine and nifedipine84
have been shown to give rapid release of the incorporated drugs at pH 6.8, but no in vitro85
studies were performed at lower pH values (Hamori et al., 2014). Eudragit has also been86
used to coat electrospun fibers (Nista et al., 2013).87
88
Some authors have also reported successful colon targeting using core/shell fibers made89
with a ES-100 shell and an ethyl cellulose core (Xu et al., 2013). It appears, however, that in90
some cases – most likely because of the very high surface-area-to-volume ratio of91
electrospun fibers – drug release can be seen at low pH even when the polymer filament is92
not soluble. Karthikeyan and co-workers generated mixed fibers of zein and ES-100 loaded93
with pantoprazole and aceclofenac and found that after 2 h immersion 0.1 N HCl, while only94
6 % of the former was released, some 25 % of the latter was freed into solution (Karthikeyan95
et al., 2012).96
97
In this work, we were interested in preparing pH-sensitive electrospun drug delivery98
systems for the anti-cancer drug 5-fluorouracil (5-FU; Figure 1). 5-FU has a very low99
molecular weight, and is very soluble in acidic media. It has been prescribed for over 55100
years, and is widely used for the treatment of colorectal, breast, gastrointestinal, and101
ovarian cancers (Rejinold et al., 2011). The drug is usually administered intravenously (due102
to its poor water solubility) or topically as an ointment, especially in the case of skin cancer.103
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Here we sought to develop systems to deliver 5-FU specifically to the lower reaches of the104
GI tract.105
106
Figure 1. The chemical structure of 5-FU.107
108
2. Materials and methods109
2.1 Materials110
Eudragit S100 (Mw = 125,000 Da) was a gift from Evonik GmbH (Darmstadt, Germany).111
Poly(vinylpyrrolidone) (PVP) K60 (Mw = 360,000 Da) was purchased from the Shanghai112
Yunhong Pharmaceutical Aids and Technology Co., Ltd. (Shanghai, China). Ethyl cellulose (6113
mPa·s to 9 mPa·s) was obtained from the Aladdin Chemistry Co., Ltd (Shanghai, China). 5-FU114
was purchased from Sigma–Aldrich (Gillingham, UK). Basic fuchsin, N,N-dimethylformamide115
(DMF), and anhydrous ethanol were provided by the Sinopharm Chemical Reagent Co., Ltd.116
(Shanghai, China). All other chemicals and reagents were of analytical grade, and were used117
as supplied. Water was distilled prior to use.118
119
2.2 Electrospinning120
A 13 % w/v Eudragit S100 (ES-100) solution was prepared in a mixture of ethanol and N,N-121
dimethylformamide (DMF; 8:2 v/v) and used as the sheath solution. A 10 % w/v solution of122
5-FU in DMF was also prepared, and used to generate four different core solutions: 1 mL of123
the 5-FU solution was combined with 1 mL of a polymer solution, as detailed in Table 1. To124
aid observation of the electrospinning process, 0.2 mg/mL of basic fuchsin was added to the125
S3 solution.126
127
128
129
130
131
132
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Table 1. The compositions of the solutions used for coaxial electrospinning.133
ID Core solution prepared froma Core solution composition (w/v) Sheath
solution (w/v)
S1 6 % PVP in ethanol and 10 % 5-FU 3 % PVP and 5 % 5-FU 13 % ES-100
S2 20 % ethyl cellulose in ethanol and 10 % 5-FU 10 % ethyl cellulose and 5 % 5-FU 13 % ES-100
S3 5 % ES-100 in ethanol/DMF and 10 % 5-FU 2.5 % ES-100 and 5 % 5-FU 13 % ES-100
S4 DMF and 10 % 5-FU 5 % 5-FU 13 % ES-100
S5 13 % ES-100 and 5 % FU in ethanol/DMF (8/2
v/v)
13 % ES-100 and 5 % 5-FU Ethanol
a All % ages are as w/v, and the 5-FU solution was prepared in DMF. Core solutions were prepared by134
combining 1 mL of the appropriate polymer solution with 1 mL of the 5-FU solution for S1 – S4.135
136
Coaxial electrospinning was performed on a setup comprising two syringe pumps (KDS100137
and KDS200, Cole-Parmer, Vernon Hills, IL, USA) and a high voltage power supply (ZGF138
60Kv/2mA, Shanghai Sute Corp., Shanghai, China). A concentric spinneret was employed for139
the electrospinning process: the outer needle had an internal diameter (I.D.) of 1.2 mm, and140
the inner needle an I.D. of 0.3 mm. The electrospinning processes were recorded using a141
digital camera (PowerShot A490, Canon, Tokyo, Japan). Following a series of optimization142
experiments, the applied voltage was fixed at 14.5 kV, the core fluid flow rate at 0.1 mL / h143
(S1 and S2) or 0.2 mL / h (S3, S4, and S5), and the sheath fluid rate at 1.5 mL / h (S1/S2) or 3144
mL / h (S3/S4/S5). Fibers were collected on a flat piece of aluminium foil placed 12 cm from145
the spinneret. All experiments were performed under ambient conditions (25 ± 2 °C; 57 ±146
6% relative humidity).147
148
2.3 Characterization149
2.3.1 Electron microscopy150
The morphology of the fibers was examined using an S-4800 field-emission scanning151
electron microscope (FESEM, Hitachi, Tokyo, Japan). The average fiber diameter was152
determined by measuring the fibers (n > 50) in SEM images, using the ImageJ software153
(National Institutes of Health, Bethesda, MD, USA). Transmission electron microscope (TEM)154
images of the samples were obtained on a JEM-3000F HR field emission TEM (JEOL, Tokyo,155
Japan). Fiber samples were collected by fixing a lacey carbon-coated copper grid to the156
collector and electrospinning directly on to this.157
158
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2.3.2 Physical form assessment159
X-ray diffraction (XRD) patterns were recorded on a D8 Advance instrument (Bruker,160
Billerica, MA, USA) using Cu Kα radiation at 40 kV and 25 mA. Differential scanning 161
calorimetry (DSC) analyses were carried out using a DSC Q2000 calorimeter (TA instruments,162
New Castle, DE, USA). Sealed samples were heated at 10 °C /min from 40 to 300 °C under a163
50 mL / min flow of nitrogen.164
165
2.3.3 IR spectroscopy166
Attenuated total reflectance Fourier transform infrared (FTIR) analysis was carried out on a167
Spectrum 100 FTIR spectrometer (PerkinElmer, Waltham, MA, USA). The scanning range was168
650–4000 cm−1, and the resolution was set at 1 cm−1.169
170
2.3.4 In vitro dissolution testing171
Drug release was quantified using a USP-II test performed on automated apparatus (PTWS172
instrument, Pharma Test, Hainburg, Germany). 50 mg of the fiber mat was inserted into a173
size 0 gelatine capsule (SpruytHillen, IJsselstein, Holland) which was in turn loaded into a174
metal sinker. Each capsule was placed in a vessel containing 750 ml of 0.1 N HCl. After 120175
min, 250 ml of 0.2 M tri-sodium phosphate (equilibrated to 37 ± 0.5 °C) was added to each176
vessel, and the pH of the solution was adjusted to pH 6.8 using 2 N HCl. The vessel was177
continuously stirred with a paddle at 50 rpm, and throughout the experiment the178
temperature of the dissolution medium was maintained at 37 ± 0.5 °C. The 5–FU released179
was assayed at 266 nm using an inline UV spectrophotometer (Cecil 2020, Cecil Instruments180
Ltd., Cambridge, UK). Data were processed using the Icalis software (Icalis Data Systems Ltd,181
Wokingham, UK). Experiments were performed in triplicate and data are reported as mean182
± S.D. To observe the fibers after 2h immersion at pH 1.0, a separate set of experiments was183
performed in which 7 – 8 mg of fibers was placed in 10 mL of 0.1 N HCl and incubated at 37184
°C for 2 h. The fiber mat was then recovered, dried, and imaged by SEM.185
186
3. Results187
3.1 The electrospinning process188
Photographs of the electrospinning process for S3 are given in Figure 2. When no voltage189
was applied, it is evident that the core and sheath solutions did not mix when they came190
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together. This indicates that the solution parameters were correctly tuned to yield a191
core/shell structure. When the applied voltage was increased to 14.5 kV a straight thinning192
jet was ejected from the compound Taylor cone; this then undergoes bending and whipping193
motions forming loops of increasing size (Figure 2(b) and (c)).194
195
196
197
198
199
200
201
202
203
Figure 2. Photographs of the S3 coaxial electrospinning process. (a) the liquid droplet at 0 kV; (b) the204
compound Taylor cone showing jets ejecting from the tip at 14.5 kV; (c) the bending and whipping movement205
of the jet at 14.5 keV; and, (d) the division of the jet at 16 kV.206
207
A further increase in the applied voltage to 16 kV led to branching of the spinning jet, giving208
two bending and whipping instability regions. Branching of the spinning jet is a complex209
phenomenon and may give rise to separation of the shell and core parts of the fibers.210
Therefore, the applied voltage was set as 14.5 kV for all subsequent electrospinning211
processes.212
213
3.2 Fiber morphology214
SEM images of the fibers produced are given in Figure 3. The fibers have smooth surfaces215
and comprise uniform structures without any ‘beads-on-a-string’ morphology visible. There216
is no evidence for any particles or phase separation present, indicating that the multiple217
components of the formulations are homogeneously mixed. Some precipitation of 5-FU was218
observed during the solution preparation process for S2, but no drug crystals can be seen in219
the fibers.220
221
222
223
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233
Figure 3. SEM images of the fibers. (a) S1; (b) S2; (c) S3; (d) S4; (e) S5; and, (f) the ends of the S3 fibers.234
235
The fiber diameters are listed in Table 2. It can be seen that all the fibers are around 1 µm in236
size, with the fibers containing S100 and 5-FU solution only as the core being larger than the237
PVP and EC containing samples.238
239
Table 2: The diameters of the Eudragit-based fibers.240
Formulation Core Shell Fiber diameter / nm
S1 PVP / 5-FU ES-100 899 ± 208
S2 EC / 5-FU ES-100 848 ± 215
S3 ES-100 / 5-FU ES-100 1275 ± 383
S4 5-FU ES-100 1033 ± 233
S5 ES-100/5-FU - 873 ± 232
241
TEM was employed to study in more detail the structures of the fibers, and the results are242
presented in Figure 4. S1, S2, S3 and S4 possess distinct core-shell structures. The S5 fibers,243
in contrast, do not show any core-shell structure; this is as expected, since the shell fluid for244
S5 comprised purely a solvent.245
246
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Figure 4. TEM images of (a) S1; (b) S2; (c) S3; (d) S4; and, (e) S5.256
257
258
3.3 Physical form259
The physical form of the fiber components was studied by X-ray diffraction (XRD) and260
differential scanning calorimetry (DSC). The resultant data are shown in Figure 5.261
262
263
264
265
266
267
268
269
Figure 5. (a) XRD and (b) DSC data for the electrospun fibers and raw materials.270
271
From the diffraction data, it is clear that 5-FU is a crystalline material with numerous272
characteristic reflections present in its XRD pattern. The polymers ES-100, PVP and EC273
display only broad haloes in their patterns, consistent with their existence as amorphous274
materials. In all cases, the XRD patterns of the composite fibers do not show any Bragg275
reflections, only the broad humps typical of amorphous materials.276
277
In DSC, 5-FU shows a sharp endothermic melting peak at 287 °C, in good agreement with278
the literature value (Krishnaiah et al., 2002). The DSC spectrum of Eudragit S100 showed a279
broad endothermic band between 55 and 100 ˚C, which can be ascribed to the loss of 280
absorbed and adsorbed water. This is followed by a second endothermic band which begins281
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at around 150 ˚C, in accordance with the literature (Chawla et al., 2012; Hu et al., 2012).  282
PVP also shows a broad dehydration endotherm between 55 and 125 °C. The EC283
thermogram contains no distinct features.284
285
The DSC traces of all the fibers do not contain a 5-FU melting endothermic peak, thus286
demonstrating the absence of crystalline material in the formulations. This is consistent with287
the XRD data. All the fiber formulations exhibit a shallow endothermic peak below 100 – 150288
°C, which is attributed to the loss of water.289
290
3.4 IR spectroscopy291
IR spectra of the raw materials and electrospun fibers are depicted in Figure 6.292
293
294
Figure 6. FTIR spectra of the fibers and raw materials.295
296
The IR spectrum of pure 5-FU shows two carbonyl (C=O) stretching at 1720 and ca. 1645297
cm-1 (Gao et al., 2007), a C-N stretch at 1243 cm-1 and a C-F stretch at 995 cm-1. The broad298
stretch between 3150- 2800 cm-1 is due to C-H and N-H stretching. The spectrum of ES-100299
displays characteristic bands of methyl and methylene C–H stretching vibrations at 2997 and300
2952 cm-1, a strong band because of carbonyl groups at 1724 cm-1 (C=O stretch) and two301
bands because of ester linkages (C–O–C stretches) at 1257 and 1148 cm-1. In the spectra of302
the fibers, the most intense peaks from ES-100 are visible at 1720 – 1724 cm-1 (C=O stretch)303
and a second peak can be seen at 1148 - 1150 cm-1 due to C–O–C stretching. The S1 fibers304
additionally show a strong peak at 1650 cm-1, which may arise either from 5-FU or from the305
PVP comprising its core. The other fibers show a shoulder to the Eudragit peak at 1720 –306
1724 cm-1, which is expected to correspond to a 5-FU carbonyl stretch; this is particularly307
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marked in S5. The peak positions are little changed in the fibers from the raw materials. The308
distinct 5-FU phonon vibrations below 1000 cm-1 (e.g. at 750 cm-1) do not appear to be309
present, but the picture is confused by the fact that ES-100 has peaks at similar310
wavenumbers. All in all, these data are consistent with the XRD and DSC data, indicating a311
molecular dispersion of 5-FU in the polymer carriers.312
313
3.5 In vitro drug release314
The in vitro drug release profiles of the different fibers are given in Figure 7. The S2 fibers315
were not studied in this assay, because the observation of precipitates in the316
electrospinning process led to concern about their homogeneity.317
318
319
Figure 7. In vitro 5-FU release from the fiber formulations. Experiments were performed in triplicate, and the320
data shown as mean ± S.D. 100% release is defined as the point at which maximum drug release was observed.321
322
These results are unexpected. Since ES-100 is insoluble at pH 1.0, it would intuitively be323
expected that the drug would release very slowly under these conditions. However, it is324
clear that in all cases 5-FU release happens rather rapidly, even at such a low pH. The single-325
fluid S5 fibers release their drug load most quickly, followed by S4 (for which the core fluid326
was a 5-FU solution only), S3 (ES-100 core), and S1 (PVP core). When the pH is raised to 6.8,327
a second burst of release is seen for all the fibers, with S3, S4 and S5 then very rapidly328
reaching maximum drug release. S1, possibly counter-intuitively given the very high329
solubility of PVP, gives a sustained release of drug over the remaining 6h of the experiment.330
331
The rapid release from S5 at pH 1.0 can be explained by a combination of two factors. First,332
5-FU is a low molecular weight and basic drug, and is very soluble at low pH. Second, the333
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very high surface-area-to-volume ratio of the fibers will result in a large amount of 5-FU334
being present at the fiber surfaces. This surface drug will be freed rapidly into solution. 5-FU335
from further inside the fibers may also be able to diffuse out through pores created by336
earlier departing drug molecules. It was observed that after 2h of immersion in 750 mL of337
the acid medium, the S5 fiber mat had virtually completely disintegrated, presumably as a338
result of the loss of a significant amount of its drug loading causing the fibers to collapse and339
separate.340
341
The rapid release of drug from the core/shell fibers is more puzzling. Although the fibers342
appear to have clear core/shell structures from TEM images, with a clear interface between343
these two compartments of the fibers, it may be that some mixing of the core and shell344
solutions occurred, resulting in some 5-FU being present at the surface of the fibers. The345
dissolution of this could yield pores through which the remaining drug in the core could346
escape. This process is somewhat more arduous than the freeing of surface drug into347
solution, and thus takes longer, leading to slower release from the core/shell fibers. Pores348
through which drug molecules could escape from the fibers could also be created by349
swelling of the S100 shell and the permeation of water into the centre of the fibers.350
351
To obtain more insight into the drug release mechanism, the fibers were imaged after 2 h352
immersion in 0.1 N HCl (see Figure 8).353
354
355
356
357
358
359
360
361
362
363
364
365
Figure 8. SEM images of the fibers recovered after 2 h immersion in HCl. (a) S1; (b) S2; (c) S3; (d) S4; and, (e)366
S5.367
368
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The fibers S2, S3, S4 and S5 appear largely unaffected by the acid treatment, as would be369
expected given the insolubility of Eudragit at this pH. However, for S3, S4 and S5, it is clear370
that there are a number of broken fibers present. The breaking of the fibers will aid the371
release of 5-FU, since it will expose sections of the core to the release medium. However,372
the area revealed by such breakages is relatively small, and thus this is not expected to be a373
major factor.374
375
In contrast, the S1 fibers are no longer visible as individual entities, having merged and376
formed an irregular and continuous sheet. This must be ascribed to the very high377
hydrophilicity of the PVP core in these fibers: water ingress through small pores in the378
Eudragit shell must have been absorbed by the PVP, causing it to swell and the fibers to379
“burst”, losing their integrity. The formation of this agglomerate will reduce the surface-380
area-to-volume ratio of the fiber mat, and can perhaps explain the sustained release381
observed for the S1 material. Attempts to model the first stage of drug release, in the pH 1.0382
buffer, were undertaken using the Peppas model (Ritger and Peppas, 1986); the resultant383
plots were decidedly non-linear, showing that simple Peppas-type release kinetics are not384
applicable to these systems.385
386
387
4. Discussion388
In this work, a family of core/shell fibers based on Eudragit S100 has been prepared and389
fully characterised. We find that the fibers have very distinct core/shell structures, but that390
even when there is no drug in the shell release at pH 1 is nevertheless rapid. In contrast to391
these findings, previous reports (Aguilar et al., 2015; Illangakoon et al., 2014; Shen et al.,392
2011; Yu et al., 2014) have shown that monolithic Eudragit fibers can preclude drug release393
at acidic pHs. In these studies, a range of APIs were used; the properties of these, together394
with those of 5-FU, are summarised in Table 3. Other than the data reported in this work,395
only the API aceclofenac showed appreciable release at low pH (Karthikeyan et al., 2012).396
397
398
399
400
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Table 3: A summary of the literature data on electrospun Eudragit fibers where dissolution at low pH has been401
explored, and the APIs incorporated.402
API Reference pKa RMM Polymer(s) in fiber
Diclofenac sodium (Shen et al., 2011; Yu et al., 2014) 4.1 318 EL-100-55
Mebeverine
hydrochloride
(Illangakoon et al., 2014) 8.1 466 EL-100-55
Paclitaxel (Aguilar et al., 2015) 10.9 854 EL-100-55 / PUa
Aceclofenac (Karthikeyan et al., 2012) 4.7 354 ES-100 / zein
Pantoprazole (Karthikeyan et al., 2012) 4.0 383 ES-100 / zein
Ketoprofen (Yu et al., 2013b) 4.45 254 EL-100-55
Helicid (Yu et al., 2013a) - 284 EL100-55
5-FU This work 8.1 130 ES-100
a PU = polyurethane.403
404
From a consideration of the data in Table 3, it is not completely clear why high levels of 5-FU405
and aceclofenac release are seen at low pH, while for all the other APIs only minimal release406
is seen. It is not possible to make completely clear comparisons because of differences in407
the polymer systems used. We have prepared monolithic EL-100-55 fibers with 5-FU and408
found substantial release at pH 1.0 (data not shown), so we do not believe that the use of409
EL-100-55 or ES-100 is a major contributory factor to the different behaviours: both are410
after all insoluble at pH 1.0. Ketoprofen and diclofenac are acidic drugs, and thus the fact411
that they do not release from EL-100-55 fibers at pH 1.0 can be attributed to their low412
solubility at this pH. Helicid is non-ionisable and poorly soluble, and thus its lack of release413
at low pH is also understandable. Paclitaxel has a very high molecular weight, and very low414
solubility, so again here the data are intuitively understandable. In contrast, 5-FU is basic,415
and releases substantially at low pH from monolithic ES-100 fibers presumably owing to its416
high solubility in acidic conditions. However, mebeverine, another basic drug, does not.417
Looking at the drug properties, the major factor that stands out is the very low molecular418
weight of 5-FU. We thus believe that it is a combination of small molecule size and high acid419
solubility which together cause the large amounts of 5-FU release observed from monolithic420
ES-100 fibers at low pH. The low molecular weight of the drug is expected to aid it diffusing421
through pores into the fibers and into solution, a situation encouraged by the favourable422
resultant dissolution energy.423
424
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It should be noted that the results obtained by Karthikeyan et al. are contradictory to this425
explanation. These authors found that aceclofenac (acidic) and pantoprazole (basic) behave426
differently, with the acidic drug releasing to a greater extent (Karthikeyan et al., 2012). This427
may be because of the inclusion of zein in their monolithic fibers, and/or suggests that the428
picture is more complex and the intermolecular interactions between the polymer matrix429
and the drug also need to be considered, even with the high surface-area-to-volume ratios430
seen with electrospun fibers.431
432
Considering the core/shell fibers, significant amounts of 5-FU release are still seen at low433
pH. This may arise for two reasons. It may be there is some mixing of the core and shell434
solutions during electrospinning (even though clear compartments are observed by TEM),435
leading to the presence of 5-FU at the surface. This can dissolve easily, leading to pores in436
the shell through which the 5-FU can escape. Alternatively, it may be that 5-FU from the437
core can simply diffuse through pores already existing in the shell. The loss of fiber438
morphology of the S1 fibers after 2h in an acid medium (Figure 8) indicates that it is possible439
for small molecules to permeate through the shell, since it is believed that water ingress led440
to this destruction. The fiber breakages observed will accelerate drug release by exposing441
some of the core to the dissolution medium, but this should be a relatively small effect442
given the small area of the core revealed in this manner. It should be noted that polymer443
solubility is no predictor of the rate of release, nor how much will release at pH 1.0: the S1444
fibers with a PVP core show much less release in acidic conditions than the S3 fibers (ES-100445
core).446
447
Although substantial release is observed in the pH 1.0 medium, the fibers prepared in this448
work nevertheless show interesting two-stage release profiles. In vivo, this would be449
expected to yield some release in the stomach and more subsequently lower in the GI tract.450
The balance between these stages can be tuned by varying the polymer composition in the451
core. Such two-stage release profiles are much sought after in pharmaceutics, and may have452
utility for the treatment of colorectal cancer.453
454
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5. Conclusions455
A series of 5-fluorouracil (5-FU) loaded electrospun fibers was prepared in this work: four456
core/shell materials with a Eudragit S100 (ES-100) shell and a drug-loaded core, and one457
monolithic fiber material in which ES-100 comprised the filament-forming polymer. The458
fibers were smooth and cylindrical in shape, and the core/shell materials clearly showed two459
distinct phases in transmission electron microscopy. The active ingredient existed in the460
amorphous form in the fibers. In contrast to previous literature reports, very significant461
amounts of drug release (around 30 – 80 % of maximum release) were seen during462
immersion in a pH 1.0 medium, despite the insolubility of ES-100 below pH 7.0. Inspection463
by electron microscopy of the fibers after 2h in pH 1.0 showed that when the core polymer464
was poly(vinyl pyrrolidone) the individual fibers had merged to form a film, while fibers with465
cores of ES-100 or drug alone were observed to have snapped and broken up into smaller466
parts in places. The monolithic ES-100 fibers additionally showed breakages. It is proposed467
that the low molecular weight of 5-FU permitted it to diffuse through pores in the ES-100468
coating, with the high acid solubility of the drug providing a thermodynamic driver for this469
to happen. In addition, the loss of fiber integrity observed is expected to provide additional470
escape routes for the 5-FU. The fiber formulations thus show two very distinct phases of471
release, with burst release immediately after immersion into a stomach-mimicking472
environment, and a second bust of release upon transfer into a pH 6.8 buffer imitating the473
small intestine.474
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